Journal of Clinical Psychopharmacology · 1988 · 127 citations · 0 references
MedicinePharmacologyPsychiatryBehavioral DisordersPsychiatric PharmacotherapyPsychopharmacologyAnxiety Disorder PharmacotherapyAnxiety DisordersAnxiolytic PharmacologyAnxiolytic PharmacotherapyAnxiolytic TherapyPsychostimulant PharmacologyAnxiety Symptom ManagementPharmacologic AnxiolysisPharmacological Anxiety ManagementPhobia TreatmentSerious Adverse Drug ReactionsSerious Adverse EventsSocial Anxiety Disorder Treatment
Thirty-two patients meeting DSM-III criteria for social phobia entered a 1-year drug treatment with tranylcypromine in dosages between 40 and 60 mg/day. After exclusion of the early dropouts, improvement was rated as marked and moderate in 62% and 17% of the sample (N = 29), respectively. Alcohol abuse was associated with a poor outcome. Side effects were frequent and in some cases delayed the attainment of efficacious dosages until the third month of treatment. No serious adverse reactions occurred. The findings, relative to efficacy, are in accordance with a previous trial with phenelzine but need confirmation in double blind controlled studies.